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Key points:  
- Standardized flow cytometry allows highly sensitive MRD measurements in virtually all BCP-
ALL patients 
- If sufficient cells are measured (>4 million), flowcytometric MRD analysis is at least as 
sensitive as current PCR-based MRD methods 
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Abstract 
 
A fully-standardized EuroFlow 8-color antibody panel and laboratory procedure was stepwise 
designed to measure minimal residual disease (MRD) in B-cell precursor (BCP) acute lymphoblastic 
leukemia (ALL) patients with a sensitivity of ≤10-5, comparable to real-time quantitative (RQ)-PCR-
based MRD detection via antigen-receptor rearrangements.  
Leukocyte markers and the corresponding antibodies and fluorochromes were selected based on their 
contribution in separating BCP-ALL cells from normal/regenerating BCP cells in multidimensional 
principal component analyses. After five multicenter design-test-evaluate-redesign phases with a total 
of 319 BCP-ALL patients at diagnosis, two 8-color antibody tubes were selected, which allowed 
separation between normal and malignant BCP cells in 99% of studied patients. These two tubes were 
tested with a new erythrocyte bulk-lysis protocol allowing acquisition of high cell numbers in 377 bone 
marrow follow-up samples of 178 BCP-ALL patients. Comparison with RQ-PCR-based MRD data 
showed a clear positive relation between the percentage concordant cases and the number of cells 
acquired. For those samples with >4 million cells acquired, concordant results were obtained in 93% of 
samples. Most discordances were clarified upon high-throughput sequencing of antigen-receptor 
rearrangements and blind multicenter re-analysis of flowcytometric data, resulting in an unprecedented 
concordance of 98% (97% for samples with MRD <0.01%). 
In conclusion, the fully-standardized EuroFlow BCP-ALL MRD strategy is applicable in >98% of 
patients with sensitivities at least similar to RQ-PCR (≤10-5), if sufficient cells (>4x106, preferably more) 
are evaluated. 
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Introduction 
 
Most current treatment protocols for B-cell precursor (BCP) acute lymphoblastic leukemia (ALL) 
include minimal residual disease (MRD) measurements, generally based on PCR analysis of 
rearranged antigen receptor genes1-3. Although flow cytometry (FCM) can be used for MRD detection 
as well4-9, studies so far indicate that the specificity and sensitivity of FCM-MRD diagnostics is inferior 
to PCR-based MRD diagnostics10-13. Nevertheless, we and others have recently shown that the use of 
6- or 7-color immunostainings combined with the introduction of new markers and new marker 
combinations significantly improved FCM-MRD analysis in BCP-ALL patients10, 12. These 
improvements were particularly related to specificity, whereas the sensitivity still appeared to be lower 
than for the PCR-based methods. To further improve FCM-based MRD diagnostics, more objective 
and efficient discrimination of BCP-ALL cells from normal BCP cells and improved sample preparation 
procedures for acquisition of larger numbers of cells are a prerequisite. 
 
Eight-color immunostainings may contribute to improve flowcytometric MRD detection in BCP-ALL 
patients. Recently, an 8-color antibody tube was developed in the ALL-REZ-BFM 2002 trial14. This 
tube contained seven antibodies (CD10, CD19, CD20, CD22, CD34, CD45, CD38) and the nucleic 
acid dye Syto41 and gave concordant MRD results with PCR-MRD data in 86.5% of samples. A 
Chinese study reported an 8-color antibody tube (CD10, CD19, CD20, CD34, CD38, CD45, CD58, 
plus CD66c or CD13/CD33 or NG2/CD15) with a sensitivity of 0.001% in 81.6% of patients 8. Shaver 
et al elegantly analyzed the relative contribution that each marker and/or pair of markers made to 
detect MRD15, and concluded that a single 8-color tube consisting of CD9, CD10, CD19, CD20, CD34, 
CD38, CD45, and CD58, could provide as much diagnostic utility as their existing three-tube panel 
with 12 markers. 
 
Within the EuroFlow Consortium (EU-FP6, LSHB-CT-2006-018708), we aimed to design standardized 
8-color immunophenotyping protocols for multicenter MRD measurement in BCP-ALL and to improve 
the sensitivity of the assay to ≤10-5 (at least comparable to PCR). First, in order to select the most 
informative markers in distinguishing BCP-ALL from normal BCP cells, we applied novel software tools 
and principal component-based analyses16, 17. In each cycle of design-test-evaluate-redesign, the 
antibody tubes were tested on BCP-ALL samples and normal and/or regenerating bone marrow (BM), 
followed by assessment of the contribution of each antibody, until satisfactory results were obtained 
after five testing rounds. Second, a flowcytometric protocol for staining and acquisition of large 
numbers of cells (>4 million) was developed, allowing theoretical sensitivities of at least 0.001% (≤10-
5). Finally, the selected antibody tubes and standardized laboratory procedures were prospectively 
validated on follow-up samples from BCP-ALL patients, using the EuroMRD PCR-MRD methods in 
parallel as gold standard2. 
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Materials and methods 
 
BCP-ALL patients and normal controls. Data were collected in seven EuroFlow centers. BM 
samples obtained from healthy donors or  patients in whom no hematological malignancy could be 
detected (e.g. BM samples submitted for lymphoma staging, neuroblastoma staging) were used as 
control BM for normal/reactive BCP cells. BM samples obtained from pediatric ALL patients after 
induction therapy (day 78 of therapy) or one year after stop of therapy, proven to be MRD-negative by 
RQ-PCR analysis, were used as source of regenerating BCP. In the first part of the study (panel 
design and optimization), 319 BCP-ALL patients which were consecutively received during five design-
test-evaluate-redesign phases  (initial phase: n=69; phase 1: n=61; phase 2: n=28; phase 3: n=78; 
phase 4: n=83) were included. In the second part of the study (MRD analysis), 377 follow-up samples 
obtained from 178 BCP-ALL patients (day 15: n= 111; day 33: n= 139; day 78: n= 107; other time 
points: n=20) were included. Patient characteristics are summarized in Table 1. The institutional 
review board of each participating center approved this study and informed consent for study 
participation was obtained from each patient and/or his/her legal guardian. 
 
Immunophenotyping MRD panel design. First, BM samples obtained from 69 BCP-ALL patients at 
diagnosis were stained with the EuroFlow BCP-ALL antibody panel (23 different antibodies in 4 8-color 
tubes)18. The subsequently designed and optimized MRD tubes were tested during phase 1 to 4 on 
diagnostic BM samples from BCP-ALL patients using the standardized EuroFlow sample preparation 
and instrument set-up protocols18 19. Data were analyzed using Infinicyt software by comparing BCP-
ALL cells with the nearest normal/reactive BCP subsets using APS plots (see Supplemental Methods) 
as illustrated in Figure 1 and Supplemental Figure 1 and 2. Regenerating BCP cells from 6 T-ALL 
patients were used as an additional negative control (Supplemental Figure 3).  
 
Immunophenotyping MRD analyses. The finally selected BCP-ALL MRD tubes were evaluated on 
BM samples obtained during follow-up of BCP-ALL patients, using an optimized bulk-lysis protocol 
(see Results)20. BM samples were processed according to this new EuroFlow bulk-lysis protocol and 
subsequently stained using the regular EuroFlow protocol19. MRD analyses and interpretation were 
performed locally and data was subsequently sent to the BCP-ALL-MRD coordinator for central 
evaluation. Initial FCM-MRD data analysis was performed using two-dimensional dot plots for 
sequential gating of BCP-ALL cells, comparable to previous studies using 4-6 color stainings10, 12. For 
this study, we provisionally defined a minimum of 10 clustered events to consider a sample as MRD 
positive (lower limit of detection, LOD) and a minimum of 40 clustered events for accurate quantitation 
of the MRD level (lower limit of quantitation, LLOQ)21. Inter-laboratory variability in data analysis was 
evaluated as described in the Supplemental Methods and Supplemental Figure 4).   
 
RQ-PCR-based MRD analyses. MRD levels were routinely determined by real-time quantitative PCR 
(RQ-PCR) analysis of rearranged immunoglobulin (IG) and/or T-cell receptor (TR) gene 
rearrangements in laboratories participating in the quality control rounds of the EuroMRD network (see 
www.EuroMRD.org)3, 22-26. RQ-PCR data, performed in triplicate, were analyzed according to the 
For personal use only.on July 17, 2018. by guest  www.bloodjournal.orgFrom 
Page 6 of 23 
 
EuroMRD guidelines, using the criteria to prevent false-negative MRD results2. Since application of 
these criteria might result in some false-positive RQ-PCR results,2  we performed next-generation 
sequencing (NGS) to confirm or to exclude the presence of MRD in discordant samples considered 
positive by RQ-PCR but negative by FCM. 
 
NGS-based MRD analyses. NGS was generally performed as described previously27. Briefly, 
depending on the IGH, TRG, and/or TRD rearrangements applied as MRD targets in the RQ-PCR 
analysis, we performed a targeted approach: the follow-up samples were amplified using the multiplex 
primer set(s) of the relevant IG/TR locus only and data analysis was focussed on the specific 
junctional region sequence (i.e. the one used for RQ-PCR analysis). The primers for TCRG were 
newly designed (Supplemental Table 1) and individual primer combinations from multiplex PCR were 
tested for sensitivity using NGS for diluted diagnostic ALL samples from patients with respective V and 
Jgamma segment combinations, all reaching the sensitivity of 10-5. All data were finally scored as 
either MRD-positive or MRD-negative.   
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Results 
 
Design and optimization of 8-color MRD labeling for BCP-ALL: In the initial phase, five antibodies 
(CD19, CD45, CD34, CD10 and CD20) were upfront selected as backbone markers since they allow 
appropriate BCP gating as well as characterization of several BCP subpopulations, and are known to 
allow discrimination between normal BCP and BCP-ALL cells10, 28, 29 30. To evaluate which other 
markers could contribute to optimal separation of BCP-ALL cells from normal/reactive BCP cells, the 
EuroFlow BCP-ALL diagnosis panel 18 was applied to 69 BCP-ALL patients as well as to 
normal/reactive BM samples. Based on principal component analysis (visualized through APS plots) 
16, 17, 19
 of the BCP-ALL cells versus normal/reactive BCP cells (analyzed per tube), CD9, CD123, 
CD66c, CD81, CD24 and CD10 appeared to be markers that were most frequently differentially 
expressed (see Supplemental Figure 5). These markers were combined with the five backbone 
markers listed above and complemented with TdT and CD58, both previously reported to be of 
relevance for BCP-ALL MRD analyses 10, 28, 29, 31. The remaining open position was filled in with 
surface membrane (Sm) IgKappa/IgLambda, as a potential exclusion maker for more mature BCPs. 
Fluorochrome positions were primarily determined based on the position of the involved markers in the 
EuroFlow BCP-ALL panel 18.  
 
The resulting three Phase-1 MRD tubes (Table 2) were subsequently tested on 61 consecutive BCP-
ALL patients at diagnosis and the discriminatory power was evaluated by comparing the leukemic 
BCP with the nearest normal BCP subset in APS plots. Whereas both tube 1 and tube 3 gave 
good/fair separation in approximately 60% of cases, tube 2 was clearly less informative (fair/good 
separation in <35% of cases)(Figure 2). When the tube providing the best separation for each patient 
was selected, good/fair separation was observed in 77% of cases. Considering only tube 1 and 3, 
good/fair separation was still observed in 71% of cases. These data indicate that tube 1 and 3 had 
complementary value and confirm the limited value of tube 2. 
To evaluate the relevance of each individual marker in discriminating BCP-ALL cells from 
normal/reactive BCP cells, those markers that received a weight over 10% in the first or second 
prinicipal component in an APS view of the nearest normal BCP cells and the BCP-ALL cells were 
selected. CD66c (80% of cases), CD9 (63%), and CD123 (55%) contributed most frequently. 
Based on these Phase-1 BCP-ALL results, the panel was redesigned: CD58, TdT, SmIgK/L, and 
CD81 were (at least provisionally) excluded, whereas CD22, which might be important for gating of B-
cells in case of CD19-targeting therapies, was included (Table 2).  
 
The Phase-2 BCP-ALL MRD tubes were evaluated on diagnostic samples from 28 consecutive BCP-
ALL patients. Good/fair separation between BCP-ALL cells and their nearest normal/reactive BCP 
counterpart was possible in approximately 75% of cases in both tubes (Figure 2), showing significant 
improvement over the Phase 1 tubes. If the best score of both tubes was used for each case, over 
85% of BCP-ALL cases showed good/fair separation from the corresponding normal BCP subset and 
in only 3 cases (12%) separation was poor. 
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During Phase-2, additional studies were performed: 1) Because of non-optimal (relatively weak) CD9 
(MEM61) staining, another CD9 clone (ML13) was evaluated with much stronger results; 2) Two newly 
available fluorochromes (APC-C750 and APC-A750) showed lower background than APC-H7 (less 
binding to apoptotic cells; no binding to monocytes); 3) More detailed evaluation of the usefulness of 
CD81 versus CD24 (re-evaluation of Phase 1 data) showed that CD81 was more frequently 
differentially expressed between normal/reactive BCP cells and BCP-ALL cells and showed that CD81 
in combination with only the backbone markers resulted in a higher percentage of cases with good 
separation than CD24 did (31% versus 20%); 4) Because CD66c and CD123 are both virtually 
negative on normal/reactive BCP cells, we tested whether these markers could be combined in the PE 
channel and concluded that background levels were not affected by combining these two markers 
(data not shown). Based on these data, the new CD9 clone was included in the MRD panel, APC-H7 
was replaced by APC-C750/A750, CD24 was replaced by CD81, and CD66c and CD123 were 
combined into one fluorescence channel. The open FITC position was used for further evaluation of 
CD58. The combined data provided the Phase-3 BCP-ALL MRD tubes (Table 2). 
 
The two Phase-3 BCP-ALL MRD tubes were evaluated on 78 BCP-ALL patients. Overall, tube 1 
resulted in good/fair separation in 90% of cases, whereas this was achieved in 82% of cases for tube 
2 (Figure 2). In the three cases for which tube 1 did not result in good separation, normal/reactive 
BCP and BCP-ALL cells could be separated in tube 2, mainly due to differential expression of CD81. 
Further evaluation showed that CD38 (~35% of cases), CD66c/CD123 (~30%), and CD81 (~19%) 
improved the separation  between normal/reactive and malignant BCP cells as compared to the five 
backbone markers only, whereas CD9, CD58 and CD22 had no or limited additional value. CD9 in 
tube 1 was therefore replaced by CD81-FITC (which demonstrated equally good staining patterns as 
CD81-APC-C750) and tube 2 was discarded.  
 
Since in a few cases the evaluated MRD tubes did still not yet result in sufficient separation between 
normal/reactive and malignant BCP cells, we evaluated several other markers reported to be of 
potential interest for MRD analysis (e.g.: CD44-FITC, CD27-PE, CD164-FITC, CD73-PE, CD49f-FITC, 
CD200-PE, CD86-FITC, and Drebrin-PE) 32-36. Based on initial testing on diagnostic BCP-ALL 
samples, CD73 and CD304 appeared to be most promising based on the level and frequency of 
overexpression (~20% for CD73 and ~40% for CD304) and their stability during follow-up (data not 
shown). Since it appeared not to be possible to combine these two markers with CD66c and CD123 in 
a single fluorescence channel (due to too high background levels), a second tube was designed; this 
tube was identical to tube 1 but with CD73/CD304 instead of CD66c/CD123 in the PE channel (Table 
2). 
 
The two Phase-4 BCP-ALL MRD tubes were run on 83 consecutive diagnostic BCP-ALL samples. 
Overexpression of CD66c/CD123 or CD73/CD304 was observed in 45% and 46% of cases, 
respectively; 31% of cases did not show overexpression of either CD66c/CD123 or CD73/CD304. 
Tube 1 resulted in good/fair separation in 89% of cases, whereas this was attained in 82% of cases for 
tube 2 (Figure 2). If the best score of both tubes was used, 99% of cases showed good/fair separation 
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between the BCP-ALL cells and the nearest normal/reactive BCP subset. Therefore, tube 1 and tube 2 
were complementary to each other and one might either decide at diagnosis which tube is best for 
monitoring the particular patient or use both tubes to have an extra internal control and more precise 
measurements. These two optimized tubes were considered to be final and ready for further 
evaluation in follow-up samples of BCP-ALL patients. 
 
Optimization of the flowcytometric MRD sample preparation protocol. We aimed for a sensitivity 
of ≤10-5, at least comparable to the sensitivity reached in RQ-PCR-based MRD analysis. If a cluster of 
10-40 BCP-ALL cells should be present to consider a sample as positive, one should acquire at least 4 
million cells in order to reach the required sensitivity. Since the cellularity of BM samples obtained 
during the early phases of treatment is frequently low37, staining whole BM samples using the regular 
EuroFlow protocols would not allow acquisition of millions of cells. We therefore designed and tested a 
new EuroFlow erythrocyte bulk-lysis procedure: sufficiently large volumes of BM, i.e. containing >10 
million cells, are lysed and the leukocytes are subsequently resuspended in a small volume of washing 
buffer. This new protocol allowed staining of 10 million cells in 100 µl cell suspension per tube 
(Supplemental Table 2).  Evaluation of this new protocol showed that the percentage of doublets did 
not increase, that the number of evaluable leukocytes increased significantly, and that there were no 
major differences in cellular composition as compared to the regular EuroFlow staining protocol 
(Figure 3). Given the large increase in the number of cells stained with this new approach, all antibody 
titers were re-evaluated; modifications appeared not to be necessary. 
 
Evaluation of the EuroFlow BCP-ALL MRD tube. To evaluate whether the newly designed high-
throughput EuroFlow BCP-ALL MRD strategy performed well, we tested the final MRD tubes on 
follow-up samples of BCP-ALL patients. Based on the immunophenotype of the BCP-ALL cells at 
diagnosis, one MRD tube was selected and subsequently used for MRD evaluation. First, 
flowcytometric MRD data obtained in 178 BCP-ALL patients were compared with routinely obtained 
PCR-MRD data. As shown in Figure 4A, the concordance between the FCM-MRD data and PCR-
based MRD data was highly dependent on the number of cells acquired by flow cytometry. In addition, 
the sensitivity of FCM-MRD (percentage samples positive by both FCM and PCR relative to samples 
positive by PCR) significantly increased when higher cell numbers were acquired (Figure 4B). 
Therefore, only samples in which MRD could clearly be detected by FCM-MRD or samples which had 
sufficient cells acquired for reaching a sensitivity of ≤10-5 were included in the subsequent analyses. 
Based on a LLOQ of 40 events, at least 4x106 cells should be acquired, which was possible in 227 out 
of 377 samples (60%). FCM-MRD data obtained in these patients was comparable to PCR-based 
MRD results in 93% of samples (Figure 5 and Table 3). All but one of the 17 discordant samples 
(seven FCM+/PCR- and ten FCM-/PCR+) had MRD levels <10-4 (Supplemental Table 2). Bland–
Altman analysis showed higher PCR-based MRD values with a mean difference of 0.34 log or factor 
2.2 (Supplemental Figure 6).  
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Detailed evaluation of discordant cases. To evaluate the discordant cases, several additional 
analyses were performed. First, flow cytometry FCS data files were blindly distributed to four 
laboratories for re-analysis of the FCM-MRD data. Out of the seven cases initially scored positive by 
FCM-MRD and negative by PCR-MRD, six were interpreted as negative by all four centers upon FCM-
MRD re-analysis, while one sample (day 15) was consistently scored positive by all four centers. 
Second, RQ-PCR-MRD data were checked for cases negative by FCM-MRD and positive by PCR-
MRD. In eight of ten cases (all confirmed to be FCM-MRD negative by re-analysis in different centers), 
PCR-MRD data were considered positive based on a single well in a single target. To further evaluate 
whether this low-level positivity was potentially caused by nonspecific amplification, NGS was used to 
confirm the possible presence of the leukemia-specific antigen receptor rearrangement. In seven out 
of nine available samples, NGS-MRD was negative, whereas MRD-positivity could be confirmed in the 
remaining two patients. Thus, 6/17 (35%) discordant cases were due to initial misinterpretation of the 
FCM-MRD data and at least 7/17 (41%) was due to over-interpretation of PCR-MRD data; the 
remaining 4 cases appeared to be truly discordant cases (Supplemental Table 3). After these 
additional evaluations the actual concordance increased to 98%. If only samples with MRD levels 
<0.01% were included, 97% gave concordant results. 
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Discussion 
 
After five phases of optimization, we finally selected two 8-color antibody tubes which only differed for 
the markers present in the PE channel (CD66c/CD123 versus CD73/CD304). These two tubes are 
comparable with 8-color BCP-ALL MRD tubes recently used in other studies, since all proposed 
panels include CD19, CD10, CD20, CD34, and CD45. In our study, these markers were considered as 
backbone markers from start onwards, based on our previous experience10, 12, 18, 28-30. Also CD38 is 
present in all proposed panels and was proven to be relevant in our present study, as well as in the 
studies of Karawajew et al.14 and Shaver et al15. The remaining two positions were completed with 
different markers: CD9, CD13/CD33, CD15/NG2, CD58 (two studies), CD66c (two studies), CD73, 
CD81, CD123, CD304, and a nucleic acid dye. In our analysis, CD9, CD58, and CD22 appeared be of 
limited value and therefore were discarded, while  Shaver and colleagues, who also applied 
mathematical modelling systems, identified these as important MRD markers15. However, they did not 
test CD66c, CD73, CD123, or CD304 and the difference between the contribution of CD9 and CD81 in 
their study was limited15. CD15/NG2 might be relevant in ALL with MLL gene rearrangements, mainly 
occurring in infants38. These cases are rare and frequently present with a pro-B-ALL 
immunophenotype which can relatively easily be distinguished from normal BCP cells and plasma 
cells39. In our study, we tested and finally selected four markers that are frequently abnormally 
expressed on BCP-ALL cells: CD66c (associated with BCR-ABL and hyperdiploidy)40, 41, CD123 
(associated with hyperdiploidy42), CD73 36, and CD304 (possibly associated with TEL-AML1)33. By 
combining two of these markers in a single fluorescence channel, abnormal expression could be 
identified in approximately 70% of BCP-ALL patients. Furthermore, in combination with the backbone 
markers and CD81, BCP-ALL cells could clearly be distinguished from normal BCP cells in virtually all 
patients. Thus, after multiple phases of multicenter testing of a wide range of leukocyte markers, 
antibody clones and fluorochrome-conjugated reagents using objective novel software tools, we were 
able to select two highly effective BCP-ALL MRD tubes. 
 
It remains to be evaluated whether the designed BCP-ALL MRD tubes can also be used during 
antibody-based therapies. Especially Blinatumomab and CAR-T-cells (targeting CD19) may hamper 
the gating of BCP based on CD19. Although alternative gating strategies can be applied (e.g. based 
on CD10, CD34 and/or CD45), one could also decide to add CD24 and/or CD22 to the current tubes 
(transforming it into a 10-color tube) in MRD-based trials involving Blinatumomab43. Addition of CD24 
and CD22 will also have the advantage that the earliest BCP cells, expressing CD24 and/or CD22 but 
not yet CD19,44 can be identified; this may be of relevance for the identification of all BCP cells in 
regenerating BM samples.  
 
In order to obtain MRD data with good sensitivity, acquisition of large numbers of cells appears to be a 
prerequisite. There is no consensus yet about the number of cells needed for a population. Most 
studies in BCP-ALL indicate a minimum number between 10 and 50 events, while a recent consensus 
report on MRD detection in multiple myeloma patients defined 20 and 50 cells as the LOD and LLOQ, 
respectively21 14, 45. Consequently, a sensitivity of 10-5 (generally reached in PCR-MRD and NGS-MRD 
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analysis), requires acquisition of ≥106 cells, preferably ≥5x106 cells. We therefore developed the new 
Euroflow bulk lysis protocol, allowing acquisition of such high cell numbers. Although the bulk lysis 
protocol contains several washing steps, which will likely result in some cell loss, there is no evidence 
for selective loss of BCP-ALL cells, given the high concordance between the final FCM-MRD results 
and the PCR-MRD results. To our best knowledge, other FCM-MRD studies so far have not acquired 
≥4x106 events and therefore could not have reached the same sensitivity as shown here, although the 
study by the ALL-REZ-BFM 2002 trial group comes close14. Our data clearly shows that acquisition of 
large numbers of cells (≥4x106) is a prerequisite for obtaining good sensitivities and data which are 
truly comparable to PCR-MRD data.  
 
We finally tested the newly designed and optimized BCP-ALL MRD tubes in combination with the bulk 
lysis protocol on follow-up samples from BCP-ALL patients and compared the FCM-MRD data with 
PCR-MRD data. The concordance between both methods (in the absence of any cut-off) was 
extremely high (93%), and was significantly better than in previous studies (82.3%10 and 86.5%14). As 
mentioned above, this increased concordance is likely due to the higher sensitivity of the current 
study, resulting from the higher number of cells analyzed. Detailed evaluation of the discordant 
samples using NGS-based approaches showed that several discrepant cases were due to over-
interpretation of the PCR-MRD data, as the involved leukemia-specific IG/TR rearrangements could 
not be detected by (qualitative) NGS analysis. Consequently, it is most likely that in these discordant 
cases the positive RQ-PCR MRD data, interpreted according to the EuroMRD criteria for prevention of 
false-negative MRD results,  are due to non-specific amplification2, 10, 46, 47 and that these samples 
actually were MRD-negative.  
 
Next to these “false-positive PCR-MRD” samples, part of the initially discordant cases could be 
explained by “false-positive FCM-MRD” results: samples were initially scored MRD-positive (generally 
at very low levels of <0.01%), but these samples were consistently scored MRD-negative upon blind 
re-analysis at four different centers. Interpretation of FCM-MRD data, especially at MRD levels 
<0.01%, is still expert-based and depends on the number of events in the suspected population, their 
distance from normal, and the homogeneity of the suspected population (clustering of suspected 
cells). Whereas the number of events may easily be defined, distance from normal, and homogeneity 
of the population are more complex to be objectively defined. Novel software tools, including 
automated gating approaches and maturation pathway analysis (Supplemental Figure 7), are 
currently being developed within the EuroFlow consortium and will facilitate more standardized and 
objective FCM-MRD measurements in the near future 37. Preliminary maturation-based FCM-MRD 
data showed very good concordance with PCR-MRD data, although further improvements are needed 
for detection of low levels of MRD (<0.01%).   
 
The NGS-MRD analyses and re-analyses of FCM-MRD data increased the concordance to an 
unprecedented rate of 98%; the remaining discordant cases are likely due to statistical variation 
around the detection limits of both assays14. Therefore, the here presented EuroFlow FCM-MRD 
strategy proved to be highly sensitive (at least comparable to PCR-MRD) and fast, and allows 
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standardized quantification of MRD in virtually all BCP-ALL patients. By increasing the number of 
acquired cells to 107 (e.g. by running both tubes with 5x106 cells), the sensitivity and robustness likely 
can even be further increased. 
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Table 1. Patient characteristics.  
 
  
Initial Phase Phase 1 Phase 2 Phase 3 Phase 4 MRD phase 
Number 69  61 
 
28 
 
78 
 
83 
 
178 
 
Age (years)             
 median 6  5  5  5  3  5  
 
min 0  1 
 
1 
 
0 
 
0 
 
0 
 
 
max 76  75 
 
17 
 
17 
 
55 
 
77 
 
Gender             
 M 35 56% 40 66% 14 50% 46 59% 43 52% 94 53% 
 
F 27 44% 21 34% 14 50% 32 41% 40 48% 84 47% 
WBC (x10e9/L)            
 
 median 13.4  8.2  13.7  10.9  15.9  8.5  
 
min 0.4  0.8 
 
1.2 
 
0.7 
 
0.5 
 
0.5 
 
 
max 818  87.6 
 
312 
 
595 
 
1250 
 
900 
 
 
No data 10  1 
 
0 
 
2 
 
19 
 
11 
 
Immunophenotype             
 pro-B-ALL 8 13% 2 3% 4 14% 5 6% 6 7% 5 3% 
 
common-ALL 44 73% 48 79% 20 71% 59 76% 56 67% 137 77% 
 
pre-B-ALL 8 13% 11 18% 4 14% 13 17% 21 25% 35 20% 
 
No data 7  0 
 
0 
 
1 
 
0 
 
1 
 
Genetic dataa             
 
TEL-AML1 6 11% 15 27% 6 27% 11 16% 11 18% 45 26% 
 
BCR-ABL 4 6% 1 2% 0 0% 3 4% 1 2% 4 2% 
 
E2A-PBX1 0 0% 3 6% 0 0% 0 0% 0 0% 4 2% 
 
MLL-AF4 4 6% 1 2% 2 7% 3 4% 4 6% 3 2% 
 
MLL other 2 3% 1 2% 1 4% 1 1% 1 2% 2 1% 
 
hyperdiplod 14 25% 27 48% 6 26% 26 37% 22 37% 67 43% 
 
hypodiploid 0 0% 1 2% 1 4% 1 1% 1 2% 2 1% 
a
 Genetic data were not available for all patients; percentages refer to positive patients per all analyzed patients. 
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Table 2. Development and design of the EuroFlow BCP-ALL MRD panela  
Phase Violet laser Blue laser Red laser 
Initial b PB PO FITC PE PerCP Cy5.5 PECy7 APC APC H7 
 CD20 CD45 CD58 CD66c CD34 CD19 CD10 CD38 
 CD9 CD45 TdT CD13 CD34 CD19 CD22 CD24 
 CD21 CD45 CD15/CD65 NG2 CD34 CD19 CD123 CD81 
1 PB PO FITC PE PerCP Cy5.5 PECy7 APC APC H7 
 CD20 CD45 CD58 CD66c CD34 CD19 CD10 CD38 
 CD20 CD45 TdT SmIgK/L CD34 CD19 CD10 CD24 
 CD20 CD45 CD9 CD123 CD34 CD19 CD10 CD81 
2 PB PO FITC PE PerCP Cy5.5 PE Cy7 APC APC H7 
 CD20 CD45 CD9 CD22 CD34 CD19 CD10 CD38 
 CD20 CD45 CD123 CD66c CD34 CD19 CD10 CD24 
3 PB PO FITC PE PerCP Cy5.5 PE Cy7 APC APC C750 
 CD20 CD45 CD9 
(ML13) 
CD66c/CD123 CD34 CD19 CD10 CD38 
 CD20 CD45 CD58 CD22 CD34 CD19 CD10 CD81 
4 PB PO FITC PE PerCP Cy5.5 PE Cy7 APC APC C750 
 CD20 CD45 CD81 CD66c/CD123 CD34 CD19 CD10 CD38 
 CD20 CD45 CD81 CD73/CD304 CD34 CD19 CD10 CD38 
a Markers that were changed as compared to the  previous panel are marked grey. 
b
 Only tube 1, 3 and 4 of the EuroFlow BCP-ALL diagnosis panel were evaluated, since most markers in tube 2 (Cyµ, SmIgK, 
SmIgL, SmIgM) were not expected to contribute to separation of normal and malignant BCP cells. 
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Table 3. Concordance between flowcytometric and molecular MRD data.a 
 
 Day 15 Day 33 Day 78 Other TP Total % % 
Concordant        
FCM+/PCR+ 102 47 11 9 169 74 93 FCM-/PCR- 1 5 31 4 41 18 
Discordant        
FCM-/PCR+ 0 5 5 0 10 4 7 FCM+/PCR- 1 4 2 0 7 3 
Total 104 61 49 13 227 100  
 
a Only samples in which MRD could clearly be detected by FCM-MRD or samples which had at least 
4x106 cells acquired were included in the analyses. Based on a LLOQ of 40 events, this allowed a 
sensitivity of at least 10-5. 
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Figure Legends 
 
 
Figure 1. Data analysis strategy used to optimize the antibody panel for distinguishing between 
BCP-ALL cells and their nearest normal/reactive BCP counterpart. First multiple normal/reactive 
BM samples and/or regenerating BM samples were merged (phase 1: n=7; phase 2: n= 11; phase 3: 
n=14; phase 4: n=10) and CD19-positive B-cells were selected. These were subdivided in four B-cell 
subsets, based on the backbone markers (CD19/CD10/CD20/CD34/CD45): CD34+ pre-B-I cells (light 
green), CD34-/CD10+/CD20- to dim pre-B-II/immature cells (dark blue), CD34-/CD10+/CD20+ 
immature/transitional B-cells (light blue), and CD34-/CD10-/CD20+ mature B-cells (dark green). Dot 
plots of CD34 versus CD10 (A.) and CD10 versus CD20 (B.) are shown. The one SD (dashed line) 
and 2SD lines (solid line) of the two most immature BCP subsets (pre-B-I (light green) and pre-B-
II/immature (dark blue)) were displayed in an APS view, which was subsequently fixed (supervised; 
C.). Each individual BCP-ALL case was added to the fixed APS plot and the normal BCP population 
nearest to each of the BCP-ALL populations was defined (D.). The BCP-ALL cells and nearest normal 
BCP subset were then visualized in a separate (non-fixed and balanced) APS plot, one using the 
backbone markers only (E.) and one using all eight markers (F.), by plotting the 1 standard deviation 
(SD) curve and 2SD curves of the two populations. To prevent an influence of the number of cells on 
the PCA, we opted to use a balanced PCA, implying a fixed ratio between normal and pathological 
events. Finally, the separation between the two populations was scored, based on: no overlap 
between 2SD curves: 3 points; overlap of the 2SD curves: 2 points; overlap of the 2SD and the 1SD 
curve: 1 point; overlap of both 1SD curves: 0 points. An example of this scoring is shown in 
Supplemental Figure 1. It should be noted that the above described strategy was only used for 
optimizing the antibody panel for the BCP-ALL MRD tubes, and not for actual MRD analyses.  
 
Figure 2. Power to distinguish BCP-ALL cells from their nearest normal BCP counterpart using 
the EuroFlow BCP-ALL MRD tubes. Data reflect the percentage of patients that reached the 
specified score, obtained as described in Supplemental Figure 1. Briefly, for each patient BCP-ALL 
cells and their nearest normal BCP subset were visualized in a (non-fixed and balanced) APS plot 
showing the median, 1SD curves and 2SD curves for both populations. Each patient was subseqently 
scored as follows: no overlap between 2SD curves: 3 points; overlap of the 2SD curves: 2 points; 
overlap of the 2SD and the 1SD curve: 1 point; overlap of both 1SD curves: 0 points. Max refers to the 
maximal score of the individual tubes. Phase 1: seven normal/reactive BM samples and 61 BCP-ALL 
patients; Phase 2: seven normal BM samples, four regenerating BM samples, and 28 BCP-ALL 
patients; Phase 3: five normal/reactive BM samples, nine regenerating BM samples, and 78 BCP-ALL 
patients; Phase 4: ten normal/reactive BM samples and 83 BCP-ALL patients).  
 
Figure 3. Evaluation of the EuroFlow bulk-lysis protocol. For reasons of comparison, each of the 
BM samples (day 15: n=15; day 33: n=15; day 78: n=12) was processed according to the standard 
EuroFlow protocol (FL) and in parallel according to the EuroFlow bulk-lysis protocol (BL). A. Number 
of leukocytes, debris and doublets, calculated as percentage of acquired events. Using the bulk-lysis 
method, significantly less debris (p=0.032 by paired t-test) and significantly more leukocytes (p=0.03 
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by paired t-test) were measured. There were no significant differences between the two methods for 
the percentage of doublets. B. Absolute number of leukocytes acquired. Using BL, on average 12-fold 
more leukocytes could be acquired (p<0.0001). Please note that we included relatively many day 15 
samples in order to be able to evaluate the impact of the two methods on the MRD levels as well. 
However, these day 15 samples generally have a very low WBC; consequently, the number of 
leukocytes acquired after BL is still relatively low in a subset of samples. C. Distribution of leukocyte 
subpopulations, defined as percentage of leukocytes. By paired t-test (two-sided), small but 
statistically significant differences were observed for T/NK cells (mean: 24% versus 26%, p=0.0047), 
granulocytes (mean: 33% versus 38%, p<0.001) and monocytes (mean: 3.2% versus 4.5%, p<0,001), 
whereas no significant differences were observed for the remaining populations. Of note, in two 
samples MRD was only detected using the bulk-lysis method (0.013% and 0.018%) but not using the 
whole BM method. In the 11 samples MRD positive by both methods, MRD levels were not 
significantly different from each other (paired t-test: p=0.30), with mean values of 6.3% and 6.7% by 
whole BM and bulk-lysed BM method, respectively. Correlation analysis showed a Spearman r of 
0.964 (95% CI: 00.857-0.991; p<0.0001). PC=plasma cells.     
 
Figure 4. Performance of FCM-MRD versus PCR-based MRD is dependent on the number of 
acquired cells. A. The percentage of discordant cases by FCM-MRD and PCR-MRD is shown for 
individual time-points (day 15, day 33, and day 78) as well as for all samples together. Data are 
presented for variable numbers of acquired cells: all samples (independent of cell number) and 
samples with at least 1, 2, 3, 4, or 5 million cells acquired. B. The sensitivity of FCM-MRD relative to 
PCR-MRD is shown for individual time-points (day 15, day 33, and day 78) as well as for all samples 
together. Data are presented for variable numbers of acquired cells: all samples (independent of cell 
number; n=377) and samples with at least 1 (n=330), 2 (n=287), 3 (n=255), 4 (n=227), or 5 million 
cells (n=191) acquired. Sensitivity is calculated as the number of samples positive by both FCM and 
PCR divided by the total number of samples positive by PCR (i.e. the reference method). 
 
Figure 5. Comparison of MRD data obtained by 8-color EuroFlow flow cytometry and routinely 
obtained molecular MRD data. Flowcytometric MRD data were compared with molecular MRD data 
and are shown for samples obtained at day 15 (A), day 33 (B), or day 78 (C). In the lower right part of 
each panel the number of FCM-/PCR+, FCM+/PCR+, FCM+/PCR-, and FCM-/PCR- is indicated. Only 
samples in which MRD could clearly be detected by FCM-MRD or samples which had sufficient cells 
acquired for reaching a sensitivity of ≤10-5 (i.e. ≥4x106 cells acquired) were included in the analyses. 
Based on a LOD of 10 events, the sensitivity of FCM-MRD was 2,5x10-6; the quantitative range (based 
on a LLOQ of 40 events) is 10-5. Consequently, FCM-MRD data between 2,5x10-6 and 10-5 should be 
considered as positive, but are below the limit of quantitation. 
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